PreOmics sheds light on $3.8m series A

PreOmics, a Germany-based mass spectrometry sampling technology business based on research from Max Planck Institute for Biochemistry, has obtained €3.3m ($3.8m) in a series A round backed by public-private partnership High-Tech Gründerfonds.
The round was led by Think.Health Ventures with participation from syndicate Business Angels.
Founded in 2016, PreOmics has devised a technology that helps prepare standardised samples for mass spectrometry research so that project teams can improve the chances of achieving robust and reproducible results.
Mass spectrometry is a scientific analysis technique that works by ionising chemical subcategories and then plotting them according to their mass-to-charge ratio.
While the technique has many scientific applications, PreOmics’ sampling kit was originally intended for proteomics research, through which mass spectrometry pinpoints molecules and chemical compounds within a given protein sample.
PreOmics was co-founded by Garwin Pichler and Nils Kulak, then researchers in the proteomics and signal transduction lab at Max Planck Institute of Biochemistry.
Pichler and Kulak have since moved to Innovation Startup Center for Biotechnology at Campus Martinsried, where the biochemistry institute is also based. The capital will go towards further product development and activities that support PreOmics’ international growth.
HTGF previously provided PreOmics with an undisclosed sum in February 2017 in what is likely to have formed part of the spinout’s seed round, though further details could not be ascertained.